慢性夹层后胸腹主动脉瘤开窗分支腔内修复的多中心跨大西洋经验
这项多中心国际研究回顾了16个中心2008至2021年连续接受开窗分支腔内主动脉修复(FB-EVAR)的246例慢性夹层后胸腹主动脉瘤(PD-TAAA)患者,技术成功率96%,30天死亡率3%,5年患者生存率65%,5年免于任何二次干预率44%。
要点
- FB-EVAR治疗慢性PD-TAAA技术成功率高(96%),30天死亡率低(3%)。
- 5年患者生存率65%,5年免于主动脉相关死亡95%±3%和93%±5%。
- 5年免于任何二次干预率44%±9%,多数为轻微手术。
核心结论
- FB-EVAR治疗慢性PD-TAAA与高技术成功率和30天低死亡率(3%)及低致残并发症率相关。
- 该手术能有效预防主动脉相关死亡,但5年患者生存率低(65%),可能归因于该队列患者显著的合并症。
- 5年免于二次干预率为44%,但大多数手术为轻微手术,显著的再干预率强调需要持续的患者监测。
研究设计与样本
- 多中心国际回顾性研究,纳入美国与欧洲16个中心2008至2021年连续接受FB-EVAR治疗I至III型PD-TAAA的患者。
- 共246例患者,76%为男性,中位年龄67岁(四分位距61-73岁),动脉瘤中位直径65 mm(四分位距59-73 mm)。
- 18例(7%)为八十岁以上患者,212例(86%)为美国麻醉医师协会分级≥3级,21例(9%)表现为包裹性破裂或有症状动脉瘤。
- 共917条肾-肠系膜血管被581个开窗(63%)和336个定向分支(37%)覆盖,平均每例患者3.7条血管。
- 数据提取自机构前瞻性维护的数据库和电子病历,所有患者接受现成或患者特定制造的開窗分支支架移植物。
主要发现
- 技术成功率为96%。
- 30天死亡率和主要不良事件率分别为3%和28%,包括新发透析1%、主要卒中1%和永久性截瘫2%。
- 平均随访24个月,Kaplan-Meier估计3年和5年患者生存率分别为79%±6%和65%±10%。
- Kaplan-Meier估计同一时间间隔免于主动脉相关死亡分别为95%±3%和93%±5%。
- 94例(38%)需要非计划二次干预,其中轻微手术64例(25%),重大手术30例(12%),1例(<1%)转为开放手术修复。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicenter international study aimed to describe outcomes of fenestrated-branched endovascular aortic repairs (FB-EVAR) in a cohort of patients treated for chronic post-dissection thoracoabdominal aortic aneurysms (PD-TAAAs). METHODS: We reviewed the clinical data of all consecutive patients treated by FB-EVAR for repair of extent I to III PD-TAAAs in 16 centers from the United States and Europe (2008-2021). Data were extracted from institutional prospectively maintained databases and electronic patient records. All patients received off-the-shelf or patient-specific manufactured fenestrated-branched stent grafts. Endpoints were any cause mortality and major adverse events at 30 days, technical success, target artery (TA) patency, freedom from TA instability, minor (endovascular with <12 Fr sheath) and major (open or ≥12 Fr sheath) secondary interventions, patient survival, and freedom from aortic-related mortality (ARM). RESULTS: A total of 246 patients (76% male; median age, 67 years [interquartile range, 61-73 years]) were treated for extent I (7%), extent II (55%), and extent III (35%) PD-TAAAs by FB-EVAR. The median aneurysm diameter was 65 mm (interquartile range, 59-73 mm). Eighteen patients (7%) were octogenarians, 212 (86%) were American Society of Anesthesiologists class ≥3, and 21 (9%) presented with contained ruptured or symptomatic aneurysms. There were 917 renal-mesenteric vessels targeted by 581 fenestrations (63%) and 336 directional branches (37%), with a mean of 3.7 vessels per patient. Technical success was 96%. Mortality and rate of major adverse events at 30 days was 3% and 28%, including disabling complications such as new onset dialysis in 1%, major stroke in 1%, and permanent paraplegia in 2%. Mean follow-up was 24 months. Kaplan-Meier (KM) estimated patient survival at 3 and 5 years was 79% ± 6% and 65% ± 10%. KM estimated freedom from ARM was 95% ± 3% and 93% ± 5% at the same intervals. Unplanned secondary interventions were needed in 94 patients (38%), including minor procedures in 64 (25%) and major procedures in 30 (12%). There was one conversion to open surgical repair (<1%). KM estimated freedom from any secondary intervention was 44% ± 9% at 5 years. KM estimated primary and secondary TA patency were 93% ± 2% and 96% ± 1% at 5 years, respectively. CONCLUSIONS: FB-EVAR for chronic PD-TAAAs was associated with high technical success and a low rate of mortality (3%) and disabling complications at 30 days. Although the procedure is effective in the prevention of ARM, patient survival was low at 5 years (65%), likely due to the significant comorbidities in this cohort of patients. Freedom from secondary interventions at 5 years was 44%, although most procedures were minor. The significant rate of reinterventions highlights the need for continued patient surveillance.
引用
- Abdelhalim MA, Tenorio ER, Oderich GS, et al. Multicenter trans-Atlantic experience with fenestrated-branched endovascular aortic repair of chronic post-dissection thoracoabdominal aortic aneurysms. J Vasc Surg. 2023. PMID: 37321524. doi:10.1016/j.jvs.2023.05.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。